Roghani Kimia, Holtby Randall J, Jahr Jonathan S
Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine at UCLA, Ronald Reagan UCLA Medical Center, 757 Westwood Plaza, Suite 3325, Los Angeles, CA 90095, USA.
J Funct Biomater. 2014 Dec 12;5(4):288-95. doi: 10.3390/jfb5040288.
For many decades, Hemoglobin-based oxygen carriers (HBOCs) have been central in the development of resuscitation agents that might provide oxygen delivery in addition to simple volume expansion. Since 80% of the world population lives in areas where fresh blood products are not available, the application of these new solutions may prove to be highly beneficial (Kim and Greenburg 2006). Many improvements have been made to earlier generation HBOCs, but various concerns still remain, including coagulopathy, nitric oxide scavenging, platelet interference and decreased calcium concentration secondary to volume expansion (Jahr et al. 2013). This review will summarize the current challenges faced in developing HBOCs that may be used clinically, in order to guide future research efforts in the field.
几十年来，基于血红蛋白的氧载体（HBOCs）一直是复苏剂研发的核心，这类复苏剂除了能简单地扩充容量外，还可能提供氧输送。由于世界上80%的人口生活在无法获得新鲜血液制品的地区，这些新解决方案的应用可能会被证明非常有益（Kim和Greenburg，2006年）。早期一代的HBOCs已经有了许多改进，但各种问题仍然存在，包括凝血病、一氧化氮清除、血小板干扰以及容量扩充导致的钙浓度降低（Jahr等人，2013年）。本综述将总结在开发可能用于临床的HBOCs过程中目前面临的挑战，以指导该领域未来的研究工作。
